{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:34:07Z","timestamp":1792708447201,"version":"4.5.0"},"reference-count":190,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04852-1","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T18:52:34Z","timestamp":1773514354000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Next generation approaches in cancer immunotherapy targeting mechanisms beyond PD1 and PDL1"],"prefix":"10.1007","volume":"17","author":[{"given":"Mohamed","family":"El-Tanani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakta Mani","family":"Satyam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Arman","family":"Rabbani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran Rashid","family":"Rangraze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail Ibrahim Ali","family":"Matalka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frezah","family":"Muhana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahia","family":"El-Tanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa A. A.","family":"Aljabali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ahmed","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhel","family":"Parvez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thantrira","family":"Porntaveetus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,14]]},"reference":[{"issue":"1","key":"4852_CR1","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/s41392-020-00348-8","volume":"5","author":"Y Cao","year":"2020","unstructured":"Cao Y, et al. Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy. Signal Transduct Target therapy. 2020;5(1):250.","journal-title":"Signal Transduct Target therapy"},{"key":"4852_CR2","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3389\/fimmu.2020.00276","volume":"11","author":"V Janelle","year":"2020","unstructured":"Janelle V, et al. T-cell immunotherapies targeting histocompatibility and tumor antigens in hematological malignancies. Front Immunol. 2020;11:276.","journal-title":"Front Immunol"},{"issue":"1","key":"4852_CR3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13046-024-03004-z","volume":"43","author":"B Cavalluzzo","year":"2024","unstructured":"Cavalluzzo B, et al. Cross-reactive CD8\u2009+\u2009T cell responses to tumor-associated antigens (TAAs) and homologous microbiota-derived antigens (MoAs). J Experimental Clin Cancer Res. 2024;43(1):87.","journal-title":"J Experimental Clin Cancer Res"},{"issue":"2","key":"4852_CR4","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41577-022-00732-1","volume":"23","author":"NK Wolf","year":"2023","unstructured":"Wolf NK, Kissiov DU, Raulet DH. Roles of natural killer cells in immunity to cancer, and applications to immunotherapy. Nat Rev Immunol. 2023;23(2):90\u2013105.","journal-title":"Nat Rev Immunol"},{"key":"4852_CR5","doi-asserted-by":"publisher","first-page":"1328193","DOI":"10.3389\/fimmu.2024.1328193","volume":"15","author":"O Goldmann","year":"2024","unstructured":"Goldmann O, Nwofor OV, Chen Q, Medina E. Mechanisms underlying immunosuppression by regulatory cells. Front Immunol. 2024;15:1328193.","journal-title":"Front Immunol"},{"issue":"15","key":"4852_CR6","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.3390\/cancers13153666","volume":"13","author":"N Nishida","year":"2021","unstructured":"Nishida N. Role of oncogenic pathways on the cancer immunosuppressive microenvironment and its clinical implications in hepatocellular carcinoma. Cancers. 2021;13(15):3666.","journal-title":"Cancers"},{"key":"4852_CR7","doi-asserted-by":"crossref","unstructured":"Borroni EM, Grizzi F. Cancer Immunoediting and beyond in 2021. 2021, MDPI. p. 13275.","DOI":"10.3390\/ijms222413275"},{"issue":"5","key":"4852_CR8","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41577-024-01111-8","volume":"25","author":"M Roerden","year":"2025","unstructured":"Roerden M, Spranger S. Cancer immune evasion, immunoediting and intratumour heterogeneity. Nat Rev Immunol. 2025;25(5):353\u201369.","journal-title":"Nat Rev Immunol"},{"key":"4852_CR9","doi-asserted-by":"publisher","first-page":"107327482412900","DOI":"10.1177\/10732748241290067","volume":"31","author":"T Amin","year":"2024","unstructured":"Amin T, et al. Immunoediting Dynamics in Glioblastoma: Implications for Immunotherapy Approaches. Cancer Control. 2024;31:10732748241290067.","journal-title":"Cancer Control"},{"issue":"1","key":"4852_CR10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12935-023-02902-0","volume":"23","author":"HE Marei","year":"2023","unstructured":"Marei HE, Hasan A, Pozzoli G, Cenciarelli C. Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired. Cancer Cell Int. 2023;23(1):64.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"4852_CR11","first-page":"1919082","volume":"2019","author":"D Lu","year":"2019","unstructured":"Lu D, et al. Beyond T cells: understanding the role of PD-1\/PD\u2010L1 in tumor\u2010associated macrophages. J Immunol Res. 2019;2019(1):1919082.","journal-title":"J Immunol Res"},{"key":"4852_CR12","doi-asserted-by":"crossref","unstructured":"Ai L, Xu A, Xu J. Roles of PD-1\/PD-L1 pathway: signaling, cancer, and beyond. Regulation of cancer Immune checkpoints: Molecular and cellular mechanisms and therapy, 2020: pp. 33\u201359.","DOI":"10.1007\/978-981-15-3266-5_3"},{"issue":"1","key":"4852_CR13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","volume":"20","author":"A Naimi","year":"2022","unstructured":"Naimi A, et al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Communication Signal. 2022;20(1):44.","journal-title":"Cell Communication Signal"},{"issue":"8","key":"4852_CR14","doi-asserted-by":"publisher","first-page":"e2428526","DOI":"10.1001\/jamanetworkopen.2024.28526","volume":"7","author":"L Sun","year":"2024","unstructured":"Sun L, et al. Overall survival, treatment duration, and rechallenge outcomes with ICI therapy for recurrent or metastatic HNSCC. JAMA Netw Open. 2024;7(8):e2428526\u20132428526.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"4852_CR15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41571-021-00564-3","volume":"19","author":"FG Dall\u2019Olio","year":"2022","unstructured":"Dall\u2019Olio FG, et al. Tumour burden and efficacy of immune-checkpoint inhibitors. Nat reviews Clin Oncol. 2022;19(2):75\u201390.","journal-title":"Nat reviews Clin Oncol"},{"issue":"10","key":"4852_CR16","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/s41571-023-00794-7","volume":"20","author":"G Mountzios","year":"2023","unstructured":"Mountzios G, et al. Immune-checkpoint inhibition for resectable non-small-cell lung cancer\u2014opportunities and challenges. Nat Reviews Clin Oncol. 2023;20(10):664\u201377.","journal-title":"Nat Reviews Clin Oncol"},{"key":"4852_CR17","unstructured":"Belluomini L. Exploring the Complex Interplay between Myeloid-Derived Suppressor Cells (MDSCs), Interleukins, and Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC). 2024."},{"key":"4852_CR18","unstructured":"Gill GS et al. Immune checkpoint inhibitors and immunosuppressive tumor microenvironment: current challenges and strategies to overcome resistance. Immunopharmacol Immunotoxicol, 2025: pp. 1\u201323."},{"issue":"1","key":"4852_CR19","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s13046-025-03519-z","volume":"44","author":"H Wang","year":"2025","unstructured":"Wang H, et al. Immunotherapy resistance in non-small cell lung cancer: from mechanisms to therapeutic opportunities. J Experimental Clin Cancer Res. 2025;44(1):250.","journal-title":"J Experimental Clin Cancer Res"},{"issue":"5","key":"4852_CR20","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/cac2.12539","volume":"44","author":"GR Khosravi","year":"2024","unstructured":"Khosravi GR, et al. Immunologic tumor microenvironment modulators for turning cold tumors hot. Cancer Commun. 2024;44(5):521\u201353.","journal-title":"Cancer Commun"},{"key":"4852_CR21","doi-asserted-by":"publisher","first-page":"1344272","DOI":"10.3389\/fimmu.2024.1344272","volume":"15","author":"P Ouyang","year":"2024","unstructured":"Ouyang P, et al. Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors. Front Immunol. 2024;15:1344272.","journal-title":"Front Immunol"},{"issue":"1","key":"4852_CR22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41392-024-01765-9","volume":"9","author":"A Hu","year":"2024","unstructured":"Hu A, et al. Harnessing innate immune pathways for therapeutic advancement in cancer. Signal Transduct Target Therapy. 2024;9(1):68.","journal-title":"Signal Transduct Target Therapy"},{"issue":"5","key":"4852_CR23","doi-asserted-by":"publisher","first-page":"880","DOI":"10.3390\/cancers17050880","volume":"17","author":"S Almawash","year":"2025","unstructured":"Almawash S. Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy. Cancers. 2025;17(5):880.","journal-title":"Cancers"},{"issue":"5","key":"4852_CR24","doi-asserted-by":"publisher","first-page":"e70345","DOI":"10.1002\/ctm2.70345","volume":"15","author":"S Xiang","year":"2025","unstructured":"Xiang S, Li S, Xu J. Unravelling T cell exhaustion through co-inhibitory receptors and its transformative role in cancer immunotherapy. Clin Translational Med. 2025;15(5):e70345.","journal-title":"Clin Translational Med"},{"issue":"1","key":"4852_CR25","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1186\/s40001-024-02203-w","volume":"29","author":"J Luo","year":"2024","unstructured":"Luo J, et al. Tim-3 pathway dysregulation and targeting in sepsis-induced immunosuppression. Eur J Med Res. 2024;29(1):583.","journal-title":"Eur J Med Res"},{"issue":"6","key":"4852_CR26","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.3390\/ijms23063207","volume":"23","author":"E Ciraolo","year":"2022","unstructured":"Ciraolo E, et al. Simultaneous genetic ablation of PD-1, LAG-3, and TIM-3 in CD8 T cells delays tumor growth and improves survival outcome. Int J Mol Sci. 2022;23(6):3207.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"4852_CR27","doi-asserted-by":"publisher","first-page":"789","DOI":"10.7150\/ijbs.106115","volume":"21","author":"X Meng","year":"2025","unstructured":"Meng X, Luo Y, Cui L, Wang S. Involvement of Tim-3 in maternal-fetal tolerance: a review of current understanding. Int J Biol Sci. 2025;21(2):789.","journal-title":"Int J Biol Sci"},{"key":"4852_CR28","doi-asserted-by":"crossref","unstructured":"Rezazadeh-Gavgani E et al. Immune Checkpoint Molecules: A Review on Pathways and Immunotherapy Implications. Immunity, Inflammation and Disease, 2025. 13(4): p. e70196.","DOI":"10.1002\/iid3.70196"},{"key":"4852_CR29","doi-asserted-by":"publisher","first-page":"175883592311860","DOI":"10.1177\/17588359231186027","volume":"15","author":"FY Kreidieh","year":"2023","unstructured":"Kreidieh FY, Tawbi HA. The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition. Therapeutic Adv Med Oncol. 2023;15:17588359231186027.","journal-title":"Therapeutic Adv Med Oncol"},{"issue":"11","key":"4852_CR30","doi-asserted-by":"publisher","first-page":"e23236","DOI":"10.1096\/fj.202301018R","volume":"37","author":"Y Li","year":"2023","unstructured":"Li Y, et al. Advancement of anti-LAG\u20103 in cancer therapy. FASEB J. 2023;37(11):e23236.","journal-title":"FASEB J"},{"issue":"1","key":"4852_CR31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40364-023-00543-z","volume":"12","author":"P Zhang","year":"2024","unstructured":"Zhang P, et al. Targeting TIGIT for cancer immunotherapy: recent advances and future directions. Biomark Res. 2024;12(1):7.","journal-title":"Biomark Res"},{"issue":"2","key":"4852_CR32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.14216\/kjco.24322","volume":"21","author":"S Zaheer","year":"2025","unstructured":"Zaheer S, Sureka N. Unlocking new frontiers: novel immune targets for next-generation cancer immunotherapy. Korean J Clin Oncol. 2025;21(2):47.","journal-title":"Korean J Clin Oncol"},{"issue":"14","key":"4852_CR33","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.3390\/cells14141087","volume":"14","author":"K Prakash","year":"2025","unstructured":"Prakash K, et al. Natural Killer Cell and Extracellular Vesicle-Based Immunotherapy in Thyroid Cancer: Advances, Challenges, and Future Perspectives. Cells. 2025;14(14):1087.","journal-title":"Cells"},{"issue":"19","key":"4852_CR34","doi-asserted-by":"publisher","first-page":"9554","DOI":"10.3390\/ijms26199554","volume":"26","author":"G Mandracci","year":"2025","unstructured":"Mandracci G, Soliman N, Khawanky NE. Overcoming Immune Therapy Resistance in Cancer Through Innate Immune Reprogramming. Int J Mol Sci. 2025;26(19):9554.","journal-title":"Int J Mol Sci"},{"key":"4852_CR35","first-page":"714822","volume":"12","author":"O Zimmermannova","year":"2021","unstructured":"Zimmermannova O, Caiado I, Ferreira AG, Pereira C-F. Cell fate reprogramming era cancer immunotherapy Front Immunol. 2021;12:714822.","journal-title":"Cell fate reprogramming era cancer immunotherapy Front Immunol"},{"issue":"8","key":"4852_CR36","doi-asserted-by":"publisher","first-page":"7493","DOI":"10.3390\/ijms24087493","volume":"24","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Sioud M. Tumor-associated macrophage subsets: shaping polarization and targeting. Int J Mol Sci. 2023;24(8):7493.","journal-title":"Int J Mol Sci"},{"key":"4852_CR37","doi-asserted-by":"publisher","first-page":"1476565","DOI":"10.3389\/fimmu.2024.1476565","volume":"15","author":"J Cao","year":"2024","unstructured":"Cao J, Liu C. Mechanistic studies of tumor-associated macrophage immunotherapy. Front Immunol. 2024;15:1476565.","journal-title":"Front Immunol"},{"key":"4852_CR38","doi-asserted-by":"publisher","first-page":"1166487","DOI":"10.3389\/fimmu.2023.1166487","volume":"14","author":"SU Khan","year":"2023","unstructured":"Khan SU, et al. Reprogramming tumor-associated macrophages as a unique approach to target tumor immunotherapy. Front Immunol. 2023;14:1166487.","journal-title":"Front Immunol"},{"issue":"7","key":"4852_CR39","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.tips.2023.04.006","volume":"44","author":"TW Stone","year":"2023","unstructured":"Stone TW, Williams RO. Modulation of T cells by tryptophan metabolites in the kynurenine pathway. Trends Pharmacol Sci. 2023;44(7):442\u201356.","journal-title":"Trends Pharmacol Sci"},{"key":"4852_CR40","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.coi.2020.12.001","volume":"70","author":"A Fiore","year":"2021","unstructured":"Fiore A, Murray PJ. Tryptophan and indole metabolism in immune regulation. Curr Opin Immunol. 2021;70:7\u201314.","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"4852_CR41","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s43046-025-00319-6","volume":"37","author":"M Devaraji","year":"2025","unstructured":"Devaraji M, Varghese B, Cheriyan. Immune-based cancer therapies: mechanistic insights, clinical progress, and future directions. J Egypt Natl Cancer Inst. 2025;37(1):62.","journal-title":"J Egypt Natl Cancer Inst"},{"issue":"1","key":"4852_CR42","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s12672-024-01195-7","volume":"15","author":"DC Joshi","year":"2024","unstructured":"Joshi DC, et al. Novel therapeutic agents in clinical trials: emerging approaches in cancer therapy. Discover Oncol. 2024;15(1):342.","journal-title":"Discover Oncol"},{"issue":"4","key":"4852_CR43","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.humimm.2020.12.005","volume":"82","author":"A Churov","year":"2021","unstructured":"Churov A, Zhulai G. Targeting adenosine and regulatory T cells in cancer immunotherapy. Hum Immunol. 2021;82(4):270\u20138.","journal-title":"Hum Immunol"},{"key":"4852_CR44","doi-asserted-by":"publisher","first-page":"1110325","DOI":"10.3389\/fimmu.2023.1110325","volume":"14","author":"X Jiang","year":"2023","unstructured":"Jiang X, et al. The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy. Front Immunol. 2023;14:1110325.","journal-title":"Front Immunol"},{"issue":"10","key":"4852_CR45","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.jtct.2022.06.025","volume":"28","author":"J Moscarelli","year":"2022","unstructured":"Moscarelli J, Zahavi D, Maynard R, Weiner LM. The next generation of cellular immunotherapy: chimeric antigen receptor-natural killer cells. Transplantation Cell therapy. 2022;28(10):650\u20136.","journal-title":"Transplantation Cell therapy"},{"key":"4852_CR46","doi-asserted-by":"publisher","first-page":"936496","DOI":"10.3389\/fimmu.2022.936496","volume":"13","author":"T Yu","year":"2022","unstructured":"Yu T, et al. Revolution of CAR engineering for next-generation immunotherapy in solid tumors. Front Immunol. 2022;13:936496.","journal-title":"Front Immunol"},{"issue":"1","key":"4852_CR47","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12967-024-06052-3","volume":"23","author":"E Pinto","year":"2025","unstructured":"Pinto E, et al. From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy. J translational Med. 2025;23(1):10.","journal-title":"J translational Med"},{"key":"4852_CR48","doi-asserted-by":"crossref","unstructured":"Zhang G et al. Current Advances and Challenges in CAR-T Therapy for Hematological and Solid Tumors. ImmunoTargets Therapy, 2025: pp. 655\u201380.","DOI":"10.2147\/ITT.S519616"},{"issue":"6","key":"4852_CR49","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.3390\/ijms23063154","volume":"23","author":"X Si","year":"2022","unstructured":"Si X, Xiao L, Brown CE, Wang D. Preclinical evaluation of CAR T cell function: in vitro and in vivo models. Int J Mol Sci. 2022;23(6):3154.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4852_CR50","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","volume":"20","author":"CL Flugel","year":"2023","unstructured":"Flugel CL, et al. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Reviews Clin Oncol. 2023;20(1):49\u201362.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"1","key":"4852_CR51","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1038\/s41467-023-41338-y","volume":"14","author":"V Bandara","year":"2023","unstructured":"Bandara V, et al. Pre-clinical validation of a pan-cancer CAR-T cell immunotherapy targeting nfP2X7. Nat Commun. 2023;14(1):5546.","journal-title":"Nat Commun"},{"issue":"3","key":"4852_CR52","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s10555-024-10185-8","volume":"43","author":"R Hou","year":"2024","unstructured":"Hou R, et al. In vivo manufacture and manipulation of CAR-T cells for better druggability. Cancer Metastasis Rev. 2024;43(3):1075\u201393.","journal-title":"Cancer Metastasis Rev"},{"issue":"7","key":"4852_CR53","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.3390\/cancers12071915","volume":"12","author":"R Mhaidly","year":"2020","unstructured":"Mhaidly R, Verhoeyen E. Humanized mice are precious tools for preclinical evaluation of CAR T and CAR NK cell therapies. Cancers. 2020;12(7):1915.","journal-title":"Cancers"},{"issue":"10","key":"4852_CR54","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/s42256-021-00383-2","volume":"3","author":"T Lu","year":"2021","unstructured":"Lu T, et al. Deep learning-based prediction of the T cell receptor\u2013antigen binding specificity. Nat Mach Intell. 2021;3(10):864\u201375.","journal-title":"Nat Mach Intell"},{"issue":"13","key":"4852_CR55","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1158\/0008-5472.CAN-24-2553","volume":"85","author":"J Zeng","year":"2025","unstructured":"Zeng J, et al. Leveraging artificial intelligence for neoantigen prediction. Cancer Res. 2025;85(13):2376\u201387.","journal-title":"Cancer Res"},{"issue":"1","key":"4852_CR56","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1186\/s12967-024-05609-6","volume":"22","author":"T Xie","year":"2024","unstructured":"Xie T, et al. Artificial intelligence: illuminating the depths of the tumor microenvironment. J Translational Med. 2024;22(1):799.","journal-title":"J Translational Med"},{"issue":"1","key":"4852_CR57","first-page":"33","volume":"22","author":"L Chang","year":"2025","unstructured":"Chang L, et al. Advancing precision medicine: the transformative role of artificial intelligence in immunogenomics, radiomics, and pathomics for biomarker discovery and immunotherapy optimization. Cancer Biology Med. 2025;22(1):33\u201347.","journal-title":"Cancer Biology Med"},{"key":"4852_CR58","doi-asserted-by":"publisher","first-page":"1661545","DOI":"10.3389\/fimmu.2025.1661545","volume":"16","author":"P Ouyang","year":"2025","unstructured":"Ouyang P, et al. Infiltration Characteristics and Regulatory Mechanisms of CD8\u2009+\u2009T Lymphocytes in Solid Tumors: Spatial Distribution, Biological Functions, and Interactions with the Immune Microenvironment. Front Immunol. 2025;16:1661545.","journal-title":"Front Immunol"},{"issue":"2","key":"4852_CR59","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3390\/biology12020218","volume":"12","author":"S Dutta","year":"2023","unstructured":"Dutta S, et al. Targets of immune escape mechanisms in cancer: basis for development and evolution of cancer immune checkpoint inhibitors. Biology. 2023;12(2):218.","journal-title":"Biology"},{"issue":"3","key":"4852_CR60","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3390\/cancers13030551","volume":"13","author":"B Seliger","year":"2021","unstructured":"Seliger B, Massa C. Immune therapy resistance and immune escape of tumors. Cancers. 2021;13(3):551.","journal-title":"Cancers"},{"issue":"10","key":"4852_CR61","doi-asserted-by":"publisher","first-page":"741","DOI":"10.3390\/cells14100741","volume":"14","author":"AF Saeed","year":"2025","unstructured":"Saeed AF. Tumor-Associated Macrophages: Polarization, Immunoregulation, and Immunotherapy. Cells. 2025;14(10):741.","journal-title":"Cells"},{"key":"4852_CR62","doi-asserted-by":"crossref","unstructured":"Chaux A. Molecular Mechanisms of Targeted Therapy Resistance in Genitourinary Tumors: A Path to New Therapeutic Horizons. 2025.","DOI":"10.20944\/preprints202506.1000.v1"},{"issue":"13","key":"4852_CR63","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.3390\/cancers16132478","volume":"16","author":"P Garg","year":"2024","unstructured":"Garg P, et al. Emerging therapeutic strategies to overcome drug resistance in cancer cells. Cancers. 2024;16(13):2478.","journal-title":"Cancers"},{"issue":"3","key":"4852_CR64","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/antib8030041","volume":"8","author":"WR Strohl","year":"2019","unstructured":"Strohl WR, Naso M. Bispecific T-cell redirection versus chimeric antigen receptor (CAR)-T cells as approaches to kill cancer cells. Antibodies. 2019;8(3):41.","journal-title":"Antibodies"},{"issue":"5","key":"4852_CR65","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40291-021-00550-6","volume":"25","author":"SK Phung","year":"2021","unstructured":"Phung SK, Miller JS, Felices M. Bi-specific and tri-specific NK cell engagers: the new avenue of targeted NK cell immunotherapy. Mol Diagn Ther. 2021;25(5):577\u201392.","journal-title":"Mol Diagn Ther"},{"issue":"1","key":"4852_CR66","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40164-025-00633-8","volume":"14","author":"LV J\u00f8rgensen","year":"2025","unstructured":"J\u00f8rgensen LV, Christensen EB, Barnkob MB, Barington T. The clinical landscape of CAR NK cells. Experimental Hematol Oncol. 2025;14(1):46.","journal-title":"Experimental Hematol Oncol"},{"issue":"1","key":"4852_CR67","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi M, et al. Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022;21(1):28.","journal-title":"Mol Cancer"},{"issue":"1","key":"4852_CR68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.69709\/CIConnect.2024.194763","volume":"1","author":"S Ahmed","year":"2024","unstructured":"Ahmed S, Mazhar MS, Shabbir MF. Neoantigen-based cancer vaccines: Current innovations, challenges and future directions in personalized immunotherapy. Cancer Immunol Connect. 2024;1(1):1\u201310.","journal-title":"Cancer Immunol Connect"},{"issue":"3","key":"4852_CR69","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3390\/cancers17030376","volume":"17","author":"I Aggeletopoulou","year":"2025","unstructured":"Aggeletopoulou I, Pantzios S, Triantos C. Personalized Immunity: Neoantigen-Based Vaccines Revolutionizing Hepatocellular Carcinoma Treatment. Cancers. 2025;17(3):376.","journal-title":"Cancers"},{"key":"4852_CR70","doi-asserted-by":"publisher","first-page":"1002313","DOI":"10.37349\/etat.2025.1002313","volume":"6","author":"MM Naffaa","year":"2025","unstructured":"Naffaa MM, Al-Ewaidat OA, Gogia S, Begiashvili V. Neoantigen-based immunotherapy: advancing precision medicine in cancer and glioblastoma treatment through discovery and innovation. Explor Target Anti-tumor Therapy. 2025;6:1002313.","journal-title":"Explor Target Anti-tumor Therapy"},{"key":"4852_CR71","doi-asserted-by":"publisher","first-page":"1568664","DOI":"10.3389\/fphar.2025.1568664","volume":"16","author":"K Ghasemi","year":"2025","unstructured":"Ghasemi K. Tiragolumab and TIGIT: pioneering the next era of cancer immunotherapy. Front Pharmacol. 2025;16:1568664.","journal-title":"Front Pharmacol"},{"key":"4852_CR72","doi-asserted-by":"crossref","unstructured":"Zaheer S, Sureka N. Unlocking New Frontiers: Novel Immune Targets for Next-Gen Cancer Immunotherapy. Authorea Preprints; 2024.","DOI":"10.22541\/au.173170806.66836515\/v1"},{"key":"4852_CR73","first-page":"1","volume":"32","author":"C Lu","year":"2024","unstructured":"Lu C, Tan Y. Promising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party. Mol Therapy Oncol. 2024;32:1.","journal-title":"Mol Therapy Oncol"},{"issue":"16","key":"4852_CR74","doi-asserted-by":"publisher","first-page":"4355","DOI":"10.1016\/j.cell.2024.07.016","volume":"187","author":"LP Andrews","year":"2024","unstructured":"Andrews LP, et al. LAG-3 and PD-1 synergize on CD8\u2009+\u2009T cells to drive T cell exhaustion and hinder autocrine IFN-\u03b3-dependent anti-tumor immunity. Cell. 2024;187(16):4355\u201372. e22.","journal-title":"Cell"},{"key":"4852_CR75","doi-asserted-by":"crossref","unstructured":"Qiu X et al. PD-1 and LAG-3 dual blockade: emerging mechanisms and potential therapeutic prospects in cancer. 2024, China Anti-Cancer Association. pp. 970\u2013976.","DOI":"10.20892\/j.issn.2095-3941.2024.0436"},{"issue":"1","key":"4852_CR76","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41392-024-02000-1","volume":"9","author":"M Hofmann","year":"2024","unstructured":"Hofmann M, Thimme R, Schamel WW. PD-1 and LAG-3: synergistic fostering of T cell exhaustion. Signal Transduct Target Therapy. 2024;9(1):291.","journal-title":"Signal Transduct Target Therapy"},{"issue":"9","key":"4852_CR77","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.3390\/cancers15092615","volume":"15","author":"C Bruss","year":"2023","unstructured":"Bruss C, et al. Immune checkpoint profiling in humanized breast cancer mice revealed cell-specific LAG-3\/PD-1\/TIM-3 co-expression and elevated PD-1\/TIM-3 secretion. Cancers. 2023;15(9):2615.","journal-title":"Cancers"},{"key":"4852_CR78","unstructured":"Pourmir I. Membrane and soluble forms of the immune checkpoint TIM-3 in clear cell renal cell carcinoma: a promising biomarker for cancer immunotherapy. Universit\u00e9 Paris Cit\u00e9; 2024."},{"key":"4852_CR79","doi-asserted-by":"publisher","first-page":"0723","DOI":"10.34133\/research.0723","volume":"8","author":"A Lin","year":"2025","unstructured":"Lin A, et al. Natural Killer Cell Immune Checkpoints and Their Therapeutic Targeting in Cancer Treatment. Research. 2025;8:0723.","journal-title":"Research"},{"issue":"1","key":"4852_CR80","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1146\/annurev-immunol-030409-101243","volume":"28","author":"M Croft","year":"2010","unstructured":"Croft M. Control of immunity by the TNFR-related molecule OX40 (CD134). Annu Rev Immunol. 2010;28(1):57\u201378.","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"4852_CR81","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1053\/j.gastro.2020.03.018","volume":"159","author":"Y Ma","year":"2020","unstructured":"Ma Y, et al. Combination of PD-1 inhibitor and OX40 agonist induces tumor rejection and immune memory in mouse models of pancreatic cancer. Gastroenterology. 2020;159(1):306\u201319. e12.","journal-title":"Gastroenterology"},{"issue":"7","key":"4852_CR82","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s11912-022-01265-5","volume":"24","author":"R Yadav","year":"2022","unstructured":"Yadav R, Redmond WL. Current clinical trial landscape of OX40 agonists. Curr Oncol Rep. 2022;24(7):951\u201360.","journal-title":"Curr Oncol Rep"},{"issue":"11","key":"4852_CR83","first-page":"4","volume":"13","author":"ER Sturgill","year":"2017","unstructured":"Sturgill ER, Redmond WL. TNFR agonists: a review of current biologics targeting OX40, 4-1BB, CD27, and GITR. Am J Hematol Oncol. 2017;13(11):4\u201315.","journal-title":"Am J Hematol Oncol"},{"issue":"2","key":"4852_CR84","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1158\/2326-6066.CIR-14-0118","volume":"3","author":"S Chen","year":"2015","unstructured":"Chen S, et al. Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector\/memory CD8 T cells in a poorly immunogenic tumor model. Cancer Immunol Res. 2015;3(2):149\u201360.","journal-title":"Cancer Immunol Res"},{"key":"4852_CR85","doi-asserted-by":"publisher","first-page":"588682","DOI":"10.3389\/fimmu.2020.588682","volume":"11","author":"J Tian","year":"2020","unstructured":"Tian J, Zhang B, Rui K, Wang S. The role of GITR\/GITRL interaction in autoimmune diseases. Front Immunol. 2020;11:588682.","journal-title":"Front Immunol"},{"issue":"14","key":"4852_CR86","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.3390\/cancers16142609","volume":"16","author":"SP Papadakos","year":"2024","unstructured":"Papadakos SP, et al. Exploring the Role of GITR\/GITRL Signaling: From Liver Disease to Hepatocellular Carcinoma. Cancers. 2024;16(14):2609.","journal-title":"Cancers"},{"issue":"23","key":"4852_CR87","doi-asserted-by":"publisher","first-page":"6196","DOI":"10.1158\/1078-0432.CCR-20-0452","volume":"26","author":"AS Balmanoukian","year":"2020","unstructured":"Balmanoukian AS, et al. Safety and clinical activity of MEDI1873, a novel GITR agonist, in advanced solid tumors. Clin Cancer Res. 2020;26(23):6196\u2013203.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4852_CR88","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/14737140.2017.1270208","volume":"17","author":"GL Beatty","year":"2017","unstructured":"Beatty GL, Li Y, Long KB. Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists. Expert Rev Anticancer Ther. 2017;17(2):175\u201386.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"2","key":"4852_CR89","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1158\/2326-6066.CIR-19-0493","volume":"8","author":"S de Silva","year":"2020","unstructured":"de Silva S, et al. CD40 enhances type I interferon responses downstream of CD47 blockade, bridging innate and adaptive immunity. Cancer Immunol Res. 2020;8(2):230\u201345.","journal-title":"Cancer Immunol Res"},{"key":"4852_CR90","doi-asserted-by":"publisher","first-page":"1656925","DOI":"10.3389\/fimmu.2025.1656925","volume":"16","author":"N Palmer","year":"2025","unstructured":"Palmer N, Khakoo SI, Sanchez-Elsner T, Vallejo AF. Enhancing natural killer cell anti-tumour activity through macrophage manipulation. Front Immunol. 2025;16:1656925.","journal-title":"Front Immunol"},{"issue":"10","key":"4852_CR91","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","volume":"22","author":"TJ Laskowski","year":"2022","unstructured":"Laskowski TJ, Biederst\u00e4dt A, Rezvani K. Natural killer cells in antitumour adoptive cell immunotherapy. Nat Rev Cancer. 2022;22(10):557\u201375.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"4852_CR92","doi-asserted-by":"publisher","first-page":"2256904","DOI":"10.1080\/21645515.2023.2256904","volume":"19","author":"T Huan","year":"2023","unstructured":"Huan T, et al. Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer. Hum Vaccines Immunotherapeutics. 2023;19(2):2256904.","journal-title":"Hum Vaccines Immunotherapeutics"},{"issue":"13","key":"4852_CR93","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.3390\/cancers13133253","volume":"13","author":"I Larionova","year":"2021","unstructured":"Larionova I, Kazakova E, Gerashchenko T, Kzhyshkowska J. New angiogenic regulators produced by TAMs: perspective for targeting tumor angiogenesis. Cancers. 2021;13(13):3253.","journal-title":"Cancers"},{"issue":"5","key":"4852_CR94","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s00432-024-05777-4","volume":"150","author":"R Huang","year":"2024","unstructured":"Huang R, Kang T, Chen S. The role of tumor-associated macrophages in tumor immune evasion. J Cancer Res Clin Oncol. 2024;150(5):238.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"4852_CR95","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41392-025-02325-5","volume":"10","author":"J Xu","year":"2025","unstructured":"Xu J, et al. Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments. Signal Transduct Target Therapy. 2025;10(1):268.","journal-title":"Signal Transduct Target Therapy"},{"key":"4852_CR96","doi-asserted-by":"publisher","first-page":"1259034","DOI":"10.3389\/fonc.2023.1259034","volume":"13","author":"M Aizaz","year":"2023","unstructured":"Aizaz M, et al. The cross-talk between macrophages and tumor cells as a target for cancer treatment. Front Oncol. 2023;13:1259034.","journal-title":"Front Oncol"},{"key":"4852_CR97","doi-asserted-by":"publisher","first-page":"1545928","DOI":"10.3389\/fimmu.2025.1545928","volume":"16","author":"K Wang","year":"2025","unstructured":"Wang K, et al. The mechanism of action and therapeutic potential of tumor-associated macrophages in tumor immune evasion. Front Immunol. 2025;16:1545928.","journal-title":"Front Immunol"},{"issue":"21","key":"4852_CR98","doi-asserted-by":"publisher","first-page":"8086","DOI":"10.1002\/cam4.3410","volume":"9","author":"Z Wang","year":"2020","unstructured":"Wang Z, Wu X. Study and analysis of antitumor resistance mechanism of PD1\/PD-L1 immune checkpoint blocker. Cancer Med. 2020;9(21):8086\u2013121.","journal-title":"Cancer Med"},{"key":"4852_CR99","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.3389\/fimmu.2017.01597","volume":"8","author":"ZY Xu-Monette","year":"2017","unstructured":"Xu-Monette ZY, Zhang M, Li J, Young KH. PD-1\/PD-L1 blockade: have we found the key to unleash the antitumor immune response? Front Immunol. 2017;8:1597.","journal-title":"Front Immunol"},{"issue":"4","key":"4852_CR100","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrclinonc.2016.168","volume":"14","author":"A Goodman","year":"2017","unstructured":"Goodman A, Patel SP, Kurzrock R. PD-1\u2013PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat reviews Clin Oncol. 2017;14(4):203\u201320.","journal-title":"Nat reviews Clin Oncol"},{"issue":"12","key":"4852_CR101","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","volume":"19","author":"A Chow","year":"2022","unstructured":"Chow A, Perica K, Klebanoff CA, Wolchok JD. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat reviews Clin Oncol. 2022;19(12):775\u201390.","journal-title":"Nat reviews Clin Oncol"},{"issue":"6","key":"4852_CR102","first-page":"499","volume":"21","author":"Z Fang","year":"2024","unstructured":"Fang Z, et al. Revolutionizing tumor immunotherapy: unleashing the power of progenitor exhausted T cells. Cancer Biology Med. 2024;21(6):499\u2013512.","journal-title":"Cancer Biology Med"},{"issue":"24","key":"4852_CR103","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.21037\/atm-22-6049","volume":"10","author":"N-H Wang","year":"2022","unstructured":"Wang N-H, et al. Radiation-induced PD-L1 expression in tumor and its microenvironment facilitates cancer-immune escape: a narrative review. Annals Translational Med. 2022;10(24):1406.","journal-title":"Annals Translational Med"},{"key":"4852_CR104","doi-asserted-by":"publisher","first-page":"1035884","DOI":"10.3389\/fonc.2022.1035884","volume":"12","author":"V Voronova","year":"2022","unstructured":"Voronova V, et al. Combination of immune checkpoint inhibitors with radiation therapy in cancer: a hammer breaking the wall of resistance. Front Oncol. 2022;12:1035884.","journal-title":"Front Oncol"},{"issue":"41","key":"4852_CR105","doi-asserted-by":"publisher","first-page":"e30561","DOI":"10.1097\/MD.0000000000030561","volume":"101","author":"R He","year":"2022","unstructured":"He R, et al. PD-1 and CTLA-4 inhibitors in combination vs. alone for the treatment of advanced melanoma: A systematic review and meta-analysis. Medicine. 2022;101(41):e30561.","journal-title":"Medicine"},{"issue":"4","key":"4852_CR106","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jtho.2020.11.025","volume":"16","author":"M Nishio","year":"2021","unstructured":"Nishio M, et al. Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 trial. J Thorac Oncol. 2021;16(4):653\u201364.","journal-title":"J Thorac Oncol"},{"issue":"6","key":"4852_CR107","first-page":"100678","volume":"5","author":"Q-A Chen","year":"2024","unstructured":"Chen Q-A, et al. Efficacy and Safety of Anti\u2013Programmed Cell Death Protein 1\/Programmed Death-Ligand 1 Antibodies Plus Chemotherapy as First-Line Treatment for NSCLC in the People\u2019s Republic of China: a Systematic Review and Meta-Analysis. JTO Clin Res Rep. 2024;5(6):100678.","journal-title":"JTO Clin Res Rep"},{"issue":"12","key":"4852_CR108","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","volume":"21","author":"T Powles","year":"2020","unstructured":"Powles T, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 2020;21(12):1563\u201373.","journal-title":"Lancet Oncol"},{"issue":"5","key":"4852_CR109","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.eururo.2023.06.006","volume":"84","author":"ER Plimack","year":"2023","unstructured":"Plimack ER, et al. Pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 KEYNOTE-426 study. Eur Urol. 2023;84(5):449\u201354.","journal-title":"Eur Urol"},{"issue":"10","key":"4852_CR110","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.3390\/cancers12102762","volume":"12","author":"X Zhao","year":"2020","unstructured":"Zhao X, Shao C. Radiotherapy-mediated immunomodulation and anti-tumor abscopal effect combining immune checkpoint blockade. Cancers. 2020;12(10):2762.","journal-title":"Cancers"},{"issue":"5","key":"4852_CR111","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40259-019-00367-0","volume":"33","author":"L Russell","year":"2019","unstructured":"Russell L, Peng KW, Russell SJ, Diaz RM. Oncolytic viruses: priming time for cancer immunotherapy. BioDrugs. 2019;33(5):485.","journal-title":"BioDrugs"},{"issue":"5","key":"4852_CR112","doi-asserted-by":"publisher","first-page":"e004167","DOI":"10.1136\/jitc-2021-004167","volume":"10","author":"L Wang","year":"2022","unstructured":"Wang L, Dunmall LSC, Cheng Z, Wang Y. Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment. J Immunother Cancer. 2022;10(5):e004167.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"4852_CR113","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","volume":"20","author":"SZ Shalhout","year":"2023","unstructured":"Shalhout SZ, Miller DM, Emerick KS, Kaufman HL. Therapy with oncolytic viruses: progress and challenges. Nat reviews Clin Oncol. 2023;20(3):160\u201377.","journal-title":"Nat reviews Clin Oncol"},{"issue":"22","key":"4852_CR114","doi-asserted-by":"publisher","first-page":"12223","DOI":"10.3390\/ijms252212223","volume":"25","author":"J Wang","year":"2024","unstructured":"Wang J, et al. Metabolic reprogramming of immune cells in the tumor microenvironment. Int J Mol Sci. 2024;25(22):12223.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4852_CR115","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41392-024-01885-2","volume":"9","author":"X Shi","year":"2024","unstructured":"Shi X, et al. Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives. Signal Transduct Target therapy. 2024;9(1):192.","journal-title":"Signal Transduct Target therapy"},{"issue":"12","key":"4852_CR116","doi-asserted-by":"publisher","first-page":"5521","DOI":"10.3390\/ijms26125521","volume":"26","author":"S Jannati","year":"2025","unstructured":"Jannati S, Patel A, Patnaik R, Banerjee Y. Oleocanthal as a Multifunctional Anti-Cancer Agent: Mechanistic Insights, Advanced Delivery Strategies, and Synergies for Precision Oncology. Int J Mol Sci. 2025;26(12):5521.","journal-title":"Int J Mol Sci"},{"key":"4852_CR117","first-page":"100023","volume":"1","author":"A Papageorgiou","year":"2024","unstructured":"Papageorgiou A. Biomarkers in Immune Checkpoint Inhibitor Cancer Treatment. Science. 2024;1:100023.","journal-title":"Science"},{"issue":"7","key":"4852_CR118","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.cell.2024.02.041","volume":"187","author":"A Passaro","year":"2024","unstructured":"Passaro A, et al. Cancer biomarkers: Emerging trends and clinical implications for personalized treatment. Cell. 2024;187(7):1617\u201335.","journal-title":"Cell"},{"issue":"2","key":"4852_CR119","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","volume":"39","author":"DL Jardim","year":"2021","unstructured":"Jardim DL, Goodman A, de Melo D, Gagliato, Kurzrock R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell. 2021;39(2):154\u201373.","journal-title":"Cancer Cell"},{"issue":"12","key":"4852_CR120","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1158\/2159-8290.CD-20-0522","volume":"10","author":"D Sha","year":"2020","unstructured":"Sha D, et al. Tumor mutational burden as a predictive biomarker in solid tumors. Cancer Discov. 2020;10(12):1808\u201325.","journal-title":"Cancer Discov"},{"issue":"1","key":"4852_CR121","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-025-01732-z","volume":"18","author":"S Sun","year":"2025","unstructured":"Sun S, et al. The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives. J Hematol Oncol. 2025;18(1):84.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"4852_CR122","first-page":"1807929","volume":"2020","author":"M Lorenzi","year":"2020","unstructured":"Lorenzi M, et al. Epidemiology of microsatellite instability high (MSI-H) and deficient mismatch repair (dMMR) in solid tumors: a structured literature review. J Oncol. 2020;2020(1):1807929.","journal-title":"J Oncol"},{"issue":"5","key":"4852_CR123","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s10120-024-01523-4","volume":"27","author":"A Ooki","year":"2024","unstructured":"Ooki A, Osumi H, Yoshino K, Yamaguchi K. Potent therapeutic strategy in gastric cancer with microsatellite instability-high and\/or deficient mismatch repair. Gastric Cancer. 2024;27(5):907.","journal-title":"Gastric Cancer"},{"issue":"13","key":"4852_CR124","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.3390\/cancers16132432","volume":"16","author":"K Turabi","year":"2024","unstructured":"Turabi K, Klute K, Radhakrishnan P. Decoding the dynamics of circulating tumor DNA in liquid biopsies. Cancers. 2024;16(13):2432.","journal-title":"Cancers"},{"issue":"7","key":"4852_CR125","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3390\/cancers16071377","volume":"16","author":"TA Allen","year":"2024","unstructured":"Allen TA. The role of circulating tumor cells as a liquid biopsy for cancer: advances, biology, technical challenges, and clinical relevance. Cancers. 2024;16(7):1377.","journal-title":"Cancers"},{"issue":"24","key":"4852_CR126","doi-asserted-by":"publisher","first-page":"5841","DOI":"10.3390\/cancers15245841","volume":"15","author":"J Ahmed","year":"2023","unstructured":"Ahmed J, Das B, Shin S, Chen A. Challenges and future directions in the management of tumor mutational burden-high (TMB-H) advanced solid malignancies. Cancers. 2023;15(24):5841.","journal-title":"Cancers"},{"issue":"8","key":"4852_CR127","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1001\/jamaoncol.2022.1981","volume":"8","author":"B Ricciuti","year":"2022","unstructured":"Ricciuti B, et al. Association of high tumor mutation burden in non\u2013small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels. JAMA Oncol. 2022;8(8):1160\u20138.","journal-title":"JAMA Oncol"},{"issue":"9","key":"4852_CR128","doi-asserted-by":"publisher","first-page":"4394","DOI":"10.3390\/ijms26094394","volume":"26","author":"JA Awosika","year":"2025","unstructured":"Awosika JA, Gulley JL, Pastor DM. Deficient Mismatch Repair and Microsatellite Instability in Solid Tumors. Int J Mol Sci. 2025;26(9):4394.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"4852_CR129","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.trecan.2023.07.002","volume":"9","author":"D Bhamidipati","year":"2023","unstructured":"Bhamidipati D, Subbiah V. Tumor-agnostic drug development in dMMR\/MSI-H solid tumors. Trends Cancer. 2023;9(10):828\u201339.","journal-title":"Trends Cancer"},{"key":"4852_CR130","first-page":"1","volume":"2","author":"M Ambrosini","year":"2025","unstructured":"Ambrosini M, et al. Epidemiology, pathogenesis, biology and evolving management of MSI-H\/dMMR cancers. Nat Reviews Clin Oncol. 2025;2:1\u201323.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"2","key":"4852_CR131","doi-asserted-by":"publisher","first-page":"124","DOI":"10.57238\/jbb.2025.7432.1143","volume":"4","author":"GA Al-Oudah","year":"2025","unstructured":"Al-Oudah GA, Alfalluji WL, Al-Ajrash AM. Checkpoint Inhibitors in Cancer Immunotherapy: Mechanisms of Action and Resistance. J Biomed Biochem. 2025;4(2):124\u201349.","journal-title":"J Biomed Biochem"},{"key":"4852_CR132","doi-asserted-by":"crossref","unstructured":"Kelloff G, Sigman CC. Opportunities for Liquid Biopsies to Meet the Challenges of Precision Medicine, in Circulating Tumor Cells: Advances in Liquid Biopsy Technologies. Springer; 2023. pp. 443\u201360.","DOI":"10.1007\/978-3-031-22903-9_17"},{"issue":"4","key":"4852_CR133","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","volume":"37","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld AJ, Hellmann MD. Acquired resistance to immune checkpoint inhibitors. Cancer Cell. 2020;37(4):443\u201355.","journal-title":"Cancer Cell"},{"issue":"11","key":"4852_CR134","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.3390\/molecules25112692","volume":"25","author":"F Mainini","year":"2020","unstructured":"Mainini F, Eccles MR. Lipid and polymer-based nanoparticle siRNA delivery systems for cancer therapy. Molecules. 2020;25(11):2692.","journal-title":"Molecules"},{"issue":"8","key":"4852_CR135","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.3390\/cancers16081589","volume":"16","author":"X Gu","year":"2024","unstructured":"Gu X, Minko T. Targeted nanoparticle-based diagnostic and treatment options for pancreatic cancer. Cancers. 2024;16(8):1589.","journal-title":"Cancers"},{"key":"4852_CR136","doi-asserted-by":"publisher","first-page":"1527600","DOI":"10.3389\/fmed.2024.1527600","volume":"11","author":"E Youssef","year":"2025","unstructured":"Youssef E, Fletcher B, Palmer D. Enhancing precision in cancer treatment: the role of gene therapy and immune modulation in oncology. Front Med. 2025;11:1527600.","journal-title":"Front Med"},{"key":"4852_CR137","doi-asserted-by":"crossref","unstructured":"Bergamaschi C, et al. Innovative strategies for T cell engagers for cancer immunotherapy. Mabs. Taylor & Francis; 2025.","DOI":"10.1080\/19420862.2025.2531223"},{"issue":"12","key":"4852_CR138","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1007\/s00432-020-03404-6","volume":"146","author":"S Huang","year":"2020","unstructured":"Huang S, Van Duijnhoven SM, Sijts AJ, Van Elsas A. Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy. J Cancer Res Clin Oncol. 2020;146(12):3111\u201322.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10396","key":"4852_CR139","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","volume":"402","author":"NW van de Donk","year":"2023","unstructured":"van de Donk NW, Zweegman S. T-cell-engaging bispecific antibodies in cancer. Lancet. 2023;402(10396):142\u201358.","journal-title":"Lancet"},{"issue":"1","key":"4852_CR140","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1021\/acssynbio.1c00256","volume":"11","author":"C Zhang","year":"2022","unstructured":"Zhang C, Zhuang Q, Liu J, Liu X. Synthetic biology in chimeric antigen receptor T (CAR T) cell engineering. ACS Synth Biol. 2022;11(1):1\u201315.","journal-title":"ACS Synth Biol"},{"issue":"7","key":"4852_CR141","doi-asserted-by":"publisher","first-page":"djv439","DOI":"10.1093\/jnci\/djv439","volume":"108","author":"H Dai","year":"2016","unstructured":"Dai H, Wang Y, Lu X, Han W. Chimeric antigen receptors modified T-cells for cancer therapy. J Natl Cancer Inst. 2016;108(7):djv439.","journal-title":"J Natl Cancer Inst"},{"key":"4852_CR142","doi-asserted-by":"crossref","unstructured":"Wells K, Liu T, Zhu L, Yang L. Immunomodulatory nanoparticles activate cytotoxic T cells for enhancement of the effect of cancer immunotherapy. Nanoscale, 2024.","DOI":"10.1039\/D4NR01780C"},{"issue":"10","key":"4852_CR143","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","volume":"21","author":"L Peng","year":"2024","unstructured":"Peng L, et al. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol. 2024;21(10):1089\u2013108.","journal-title":"Cell Mol Immunol"},{"issue":"17","key":"4852_CR144","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.3390\/cancers17172898","volume":"17","author":"S Rafii","year":"2025","unstructured":"Rafii S, et al. Advancing CAR T-Cell Therapy in Solid Tumors: Current Landscape and Future Directions. Cancers. 2025;17(17):2898.","journal-title":"Cancers"},{"issue":"24","key":"4852_CR145","first-page":"32","volume":"7","author":"I Selmi","year":"2025","unstructured":"Selmi I. Oncolytic Viruses: Mechanisms, Engineering Strategies, and Clinical Advances. Adv Ther J. 2025;7(24):32\u201341.","journal-title":"Adv Ther J"},{"issue":"4","key":"4852_CR146","doi-asserted-by":"publisher","first-page":"588","DOI":"10.3390\/cancers13040588","volume":"13","author":"K-T Jin","year":"2021","unstructured":"Jin K-T, et al. Oncolytic virotherapy in solid tumors: the challenges and achievements. Cancers. 2021;13(4):588.","journal-title":"Cancers"},{"key":"4852_CR147","doi-asserted-by":"publisher","first-page":"543","DOI":"10.30574\/wjarr.2024.21.1.2585","volume":"21","author":"MT Bayode","year":"2024","unstructured":"Bayode MT, et al. Modulating the immunosuppressive tumor microenvironment: Multi-synergistic cancer therapeutic approach with oncolytic viruses. World J Adv Res Reviews. 2024;21:543\u201359.","journal-title":"World J Adv Res Reviews"},{"key":"4852_CR148","first-page":"396","volume":"5","author":"FG Jenkins","year":"2021","unstructured":"Jenkins FG, Johnson JE, Collichio F, Ollila DW. Talimogene laherparepvec and novel injectable oncolytic viruses in the management of metastatic melanoma. J Transl Genet Genom. 2021;5:396\u2013413.","journal-title":"J Transl Genet Genom"},{"issue":"1","key":"4852_CR149","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s40364-025-00808-9","volume":"13","author":"Z Wang","year":"2025","unstructured":"Wang Z, Gu Y, Sun X, Huang H. Computation strategies and clinical applications in neoantigen discovery towards precision cancer immunotherapy. Biomark Res. 2025;13(1):96.","journal-title":"Biomark Res"},{"issue":"5","key":"4852_CR150","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1158\/2159-8290.CD-20-1575","volume":"11","author":"RG Gupta","year":"2021","unstructured":"Gupta RG, Li F, Roszik J, Liz\u00e9e G. Exploiting tumor neoantigens to target cancer evolution: current challenges and promising therapeutic approaches. Cancer Discov. 2021;11(5):1024\u201339.","journal-title":"Cancer Discov"},{"key":"4852_CR151","doi-asserted-by":"publisher","first-page":"e82813","DOI":"10.7554\/eLife.82813","volume":"12","author":"P Bradley","year":"2023","unstructured":"Bradley P. Structure-based prediction of T cell receptor: peptide-MHC interactions. elife. 2023;12:e82813.","journal-title":"elife"},{"issue":"4","key":"4852_CR152","first-page":"274","volume":"21","author":"X Li","year":"2024","unstructured":"Li X, et al. Neoantigen cancer vaccines: a new star on the horizon. Cancer Biology Med. 2024;21(4):274\u2013311.","journal-title":"Cancer Biology Med"},{"key":"4852_CR153","doi-asserted-by":"publisher","first-page":"114312","DOI":"10.1016\/j.addr.2022.114312","volume":"186","author":"GP Dunn","year":"2022","unstructured":"Dunn GP, Sherpa N, Manyanga J, Johanns TM. Considerations for personalized neoantigen vaccination in Malignant glioma. Adv Drug Deliv Rev. 2022;186:114312.","journal-title":"Adv Drug Deliv Rev"},{"issue":"34","key":"4852_CR154","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1111\/1759-7714.15126","volume":"14","author":"S Su","year":"2023","unstructured":"Su S, et al. Recent advances in neoantigen vaccines for treating non-small cell lung cancer. Thorac Cancer. 2023;14(34):3361\u20138.","journal-title":"Thorac Cancer"},{"issue":"1","key":"4852_CR155","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12943-023-01744-8","volume":"22","author":"Z Yuan","year":"2023","unstructured":"Yuan Z, et al. Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments. Mol Cancer. 2023;22(1):48.","journal-title":"Mol Cancer"},{"issue":"1","key":"4852_CR156","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13046-025-03377-9","volume":"44","author":"Y Yang","year":"2025","unstructured":"Yang Y, et al. Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy. J Experimental Clin Cancer Res. 2025;44(1):145.","journal-title":"J Experimental Clin Cancer Res"},{"issue":"12","key":"4852_CR157","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1002\/ijc.34921","volume":"154","author":"H Wang","year":"2024","unstructured":"Wang H, et al. Shaping the immune-suppressive microenvironment on tumor\u2010associated myeloid cells through tumor\u2010derived exosomes. Int J Cancer. 2024;154(12):2031\u201342.","journal-title":"Int J Cancer"},{"issue":"5","key":"4852_CR158","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.3390\/cells10051006","volume":"10","author":"Z Fu","year":"2021","unstructured":"Fu Z, et al. Tumour hypoxia-mediated immunosuppression: mechanisms and therapeutic approaches to improve cancer immunotherapy. Cells. 2021;10(5):1006.","journal-title":"Cells"},{"issue":"12","key":"4852_CR159","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1080\/17425247.2020.1814735","volume":"17","author":"S Gouarderes","year":"2020","unstructured":"Gouarderes S, Mingotaud A-F, Vicendo P, Gibot L. Vascular and extracellular matrix remodeling by physical approaches to improve drug delivery at the tumor site. Expert Opin Drug Deliv. 2020;17(12):1703\u201326.","journal-title":"Expert Opin Drug Deliv"},{"issue":"3","key":"4852_CR160","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ccell.2023.01.009","volume":"41","author":"EN Arner","year":"2023","unstructured":"Arner EN, Rathmell JC. Metabolic programming and immune suppression in the tumor microenvironment. Cancer Cell. 2023;41(3):421\u201333.","journal-title":"Cancer Cell"},{"key":"4852_CR161","doi-asserted-by":"publisher","first-page":"954992","DOI":"10.3389\/fimmu.2022.954992","volume":"13","author":"MT Bilotta","year":"2022","unstructured":"Bilotta MT, Antignani A, Fitzgerald DJ. Managing the TME to improve the efficacy of cancer therapy. Front Immunol. 2022;13:954992.","journal-title":"Front Immunol"},{"issue":"1","key":"4852_CR162","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12943-025-02323-9","volume":"24","author":"S Liu","year":"2025","unstructured":"Liu S, et al. Drug-induced tolerant persisters in tumor: Mechanism, vulnerability and perspective implication for clinical treatment. Mol Cancer. 2025;24(1):150.","journal-title":"Mol Cancer"},{"key":"4852_CR163","doi-asserted-by":"publisher","first-page":"1340702","DOI":"10.3389\/fimmu.2024.1340702","volume":"15","author":"D Lv","year":"2024","unstructured":"Lv D, et al. Crosstalk between T lymphocyte and extracellular matrix in tumor microenvironment. Front Immunol. 2024;15:1340702.","journal-title":"Front Immunol"},{"issue":"11","key":"4852_CR164","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.1039\/D1CS00343G","volume":"51","author":"Y Ju","year":"2022","unstructured":"Ju Y, et al. Nanostructured particles assembled from natural building blocks for advanced therapies. Chem Soc Rev. 2022;51(11):4287\u2013336.","journal-title":"Chem Soc Rev"},{"issue":"2","key":"4852_CR165","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1080\/14728214.2025.2504376","volume":"30","author":"D Li","year":"2025","unstructured":"Li D, Rudloff U. Emerging therapeutics targeting tumor-associated macrophages for the treatment of solid organ cancers. Expert Opin Emerg Drugs. 2025;30(2):109\u201347.","journal-title":"Expert Opin Emerg Drugs"},{"issue":"2","key":"4852_CR166","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3390\/cancers13020210","volume":"13","author":"M Haist","year":"2021","unstructured":"Haist M, Stege H, Grabbe S, Bros M. The functional crosstalk between myeloid-derived suppressor cells and regulatory T cells within the immunosuppressive tumor microenvironment. Cancers. 2021;13(2):210.","journal-title":"Cancers"},{"issue":"24","key":"4852_CR167","doi-asserted-by":"publisher","first-page":"6293","DOI":"10.3390\/cancers13246293","volume":"13","author":"K Bullock","year":"2021","unstructured":"Bullock K, Richmond A. Suppressing MDSC recruitment to the tumor microenvironment by antagonizing CXCR2 to enhance the efficacy of immunotherapy. Cancers. 2021;13(24):6293.","journal-title":"Cancers"},{"issue":"1","key":"4852_CR168","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13073-022-01037-7","volume":"14","author":"RC Newsome","year":"2022","unstructured":"Newsome RC, et al. Interaction of bacterial genera associated with therapeutic response to immune checkpoint PD-1 blockade in a United States cohort. Genome Med. 2022;14(1):35.","journal-title":"Genome Med"},{"issue":"10","key":"4852_CR169","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1158\/2326-6066.CIR-19-1014","volume":"8","author":"Z Peng","year":"2020","unstructured":"Peng Z, et al. The gut microbiome is associated with clinical response to anti\u2013PD-1\/PD-L1 immunotherapy in gastrointestinal cancer. Cancer Immunol Res. 2020;8(10):1251\u201361.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"4852_CR170","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40364-024-00607-8","volume":"12","author":"C Zhu","year":"2024","unstructured":"Zhu C, et al. Gut microbiota and metabolites signatures of clinical response in anti-PD-1\/PD-L1 based immunotherapy of biliary tract cancer. Biomark Res. 2024;12(1):56.","journal-title":"Biomark Res"},{"issue":"12","key":"4852_CR171","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.3390\/biom14121571","volume":"14","author":"V Fertitta","year":"2024","unstructured":"Fertitta V, et al. Akkermansia muciniphila-and Pathogenic Bacteria-Derived Endotoxins Differently Regulate Human Dendritic Cell Generation and \u03b3\u03b4 T Lymphocyte Activation. Biomolecules. 2024;14(12):1571.","journal-title":"Biomolecules"},{"issue":"1","key":"4852_CR172","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s12016-025-09093-8","volume":"68","author":"EJ Han","year":"2025","unstructured":"Han EJ, Ahn J-S, Chae YJ, Chung H-J. Immunomodulatory Roles of Faecalibacterium prausnitzii and Akkermansia muciniphila in Autoimmune Diseases: Mechanistic Insights and Therapeutic Potential. Clin Rev Allergy Immunol. 2025;68(1):77.","journal-title":"Clin Rev Allergy Immunol"},{"key":"4852_CR173","unstructured":"Tran D. Impact of concurrent antibiotic & CORTICOSTEROID use on Efficacy of immune checkpoint inhibitors. University of Minnesota; 2023."},{"issue":"3","key":"4852_CR174","doi-asserted-by":"publisher","first-page":"e472902","DOI":"10.1200\/EDBK-25-472902","volume":"45","author":"A Elkrief","year":"2025","unstructured":"Elkrief A, et al. Gut Microbiota in Immuno-Oncology: A Practical Guide for Medical Oncologists with a Focus on Antibiotics Stewardship. Am Soc Clin Oncol Educational Book. 2025;45(3):e472902.","journal-title":"Am Soc Clin Oncol Educational Book"},{"key":"4852_CR175","doi-asserted-by":"publisher","first-page":"102036","DOI":"10.1016\/j.toxrep.2025.102036","volume":"1","author":"MA Siddiqui","year":"2025","unstructured":"Siddiqui MA, Usmani A, Ansari MN, Almoselhy RI. Immune-related adverse events in immunotherapy: Challenges in diagnosis, monitoring, and management. Toxicol Rep. 2025;1:102036.","journal-title":"Toxicol Rep"},{"key":"4852_CR176","doi-asserted-by":"publisher","first-page":"1462307","DOI":"10.3389\/fmed.2024.1462307","volume":"11","author":"C Sainatham","year":"2024","unstructured":"Sainatham C, et al. The current socioeconomic and regulatory landscape of immune effector cell therapies. Front Med. 2024;11:1462307.","journal-title":"Front Med"},{"issue":"1","key":"4852_CR177","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41746-025-01471-y","volume":"8","author":"E Fountzilas","year":"2025","unstructured":"Fountzilas E, et al. Convergence of evolving artificial intelligence and machine learning techniques in precision oncology. NPJ Digit Med. 2025;8(1):75.","journal-title":"NPJ Digit Med"},{"key":"4852_CR178","unstructured":"Suura SR. Integrating Artificial Intelligence, Machine Learning, and Big Data with Genetic Testing and Genomic Medicine to Enable Earlier, Personalized Health Interventions. Deep Science Publishing; 2025."},{"key":"4852_CR179","doi-asserted-by":"publisher","first-page":"1620572","DOI":"10.3389\/frai.2025.1620572","volume":"8","author":"E Elfatimi","year":"2025","unstructured":"Elfatimi E, Lekbach Y, Prakash S, BenMohamed L. Artificial intelligence and machine learning in the development of vaccines and immunotherapeutics\u2014yesterday, today, and tomorrow. Front Artif Intell. 2025;8:1620572.","journal-title":"Front Artif Intell"},{"issue":"2","key":"4852_CR180","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/biochem5020005","volume":"5","author":"H Kong","year":"2025","unstructured":"Kong H. Advances in personalized Cancer vaccine development: AI applications from neoantigen discovery to mRNA formulation. BioChem. 2025;5(2):5.","journal-title":"BioChem"},{"key":"4852_CR181","unstructured":"Omar M et al. Multiplex imaging analysis in pathology: a comprehensive review on analytical approaches and digital toolkits. arXiv preprint arXiv:2411.00948, 2024."},{"key":"4852_CR182","doi-asserted-by":"publisher","first-page":"1568456","DOI":"10.3389\/fimmu.2025.1568456","volume":"16","author":"C Bungaro","year":"2025","unstructured":"Bungaro C, Guida M, Apollonio B. Spatial proteomics of the tumor microenvironment in melanoma: current insights and future directions. Front Immunol. 2025;16:1568456.","journal-title":"Front Immunol"},{"issue":"11","key":"4852_CR183","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12032-025-03042-3","volume":"42","author":"AM Alamri","year":"2025","unstructured":"Alamri AM, Assiri AA, Khan B, Khan NU. Next-generation oncology: integrative therapeutic frontiers at the crossroads of precision genomics, immuno-engineering, and tumor microenvironment modulation. Med Oncol. 2025;42(11):1\u201320.","journal-title":"Med Oncol"},{"issue":"1","key":"4852_CR184","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/diseases13010024","volume":"13","author":"DB Olawade","year":"2025","unstructured":"Olawade DB, et al. Integrating AI into cancer immunotherapy\u2014A narrative review of current applications and future directions. Diseases. 2025;13(1):24.","journal-title":"Diseases"},{"issue":"02","key":"4852_CR185","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.30574\/ijsra.2024.13.2.2450","volume":"13","author":"F Ekundayo","year":"2024","unstructured":"Ekundayo F. Reinforcement learning in treatment pathway optimization: A case study in oncology. Int J Sci Res Archive. 2024;13(02):2187\u2013205.","journal-title":"Int J Sci Res Archive"},{"key":"4852_CR186","first-page":"2","volume":"33","author":"L Abdo","year":"2025","unstructured":"Abdo L, Batista-Silva LR, Bonamino MH. Cost-effective strategies for CAR-T cell therapy manufacturing. Mol Therapy Oncol. 2025;33:2.","journal-title":"Mol Therapy Oncol"},{"key":"4852_CR187","first-page":"1","volume":"2","author":"Y-R Li","year":"2025","unstructured":"Li Y-R, Zhu Y, Halladay T, Yang L. In vivo CAR engineering for immunotherapy. Nat Rev Immunol. 2025;2:1\u201320.","journal-title":"Nat Rev Immunol"},{"key":"4852_CR188","first-page":"1","volume":"2","author":"A Esmaeilzadeh","year":"2025","unstructured":"Esmaeilzadeh A, et al. State of the art in CAR-based therapy: In vivo CAR production as a revolution in cell-based cancer treatment. Cell Oncol. 2025;2:1\u201325.","journal-title":"Cell Oncol"},{"issue":"1","key":"4852_CR189","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s43586-024-00348-w","volume":"4","author":"US Tretbar","year":"2024","unstructured":"Tretbar US, et al. Non-viral vectors for chimeric antigen receptor immunotherapy. Nat Reviews Methods Primers. 2024;4(1):74.","journal-title":"Nat Reviews Methods Primers"},{"key":"4852_CR190","doi-asserted-by":"publisher","first-page":"867013","DOI":"10.3389\/fimmu.2022.867013","volume":"13","author":"A Moretti","year":"2022","unstructured":"Moretti A, et al. The past, present, and future of non-viral CAR T cells. Front Immunol. 2022;13:867013.","journal-title":"Front Immunol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04852-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04852-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04852-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:08:10Z","timestamp":1781640490000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04852-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,14]]},"references-count":190,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4852"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04852-1","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,14]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This review did not involve any human participants, animal subjects, or biological materials. Therefore, ethical approval and informed consent were not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This manuscript is original, has not been published previously, and is not under consideration for publication elsewhere.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Dual publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"613"}}